Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03443076 · ClinicalTrials.gov registry record · NA
Bioavailability of EPA + DHA in a SMEDS Formulation
A NA study of Bioavailability, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 2
- Study locations
NCT03443076 is a NA study of Bioavailability that has completed, run by Midwest Center for Metabolic and Cardiovascular Research. The registered enrollment target is 24 participants, below the 35-participant average among 8 other Bioavailability trials with a reported enrollment target (31% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT03443076, a NA study of Bioavailability, has completed, sponsored by Midwest Center for Metabolic and Cardiovascular Research.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study will assess the relative bioavailability of 500 mg eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) in a self-micro-emulsifying delivery system (SMEDS) formulation compared with a standard omega-3-acid ethyl ester product in healthy men and women.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT EPA + DHA in SMEDS Formulation
- OTHER Lovaza (active comparator; already FDA approved)
Study Locations (2)
Florida
- MB Clinical Research, LLC - Boca Raton
Illinois
- Great Lakes Clinical Trials - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2018-02-16 |
| Est. Completion | 2018-04-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03443076
The ClinicalTrials.gov registry entry for NCT03443076 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 35-participant average among 8 other Bioavailability trials with a reported enrollment target (31% lower). The listed sponsor is Midwest Center for Metabolic and Cardiovascular Research, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bioavailability appearing as the primary indexed condition, and to 2 interventions - of which EPA + DHA in SMEDS Formulation is the first listed.
NCT03443076 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT03443076 about?
NCT03443076 is a clinical study titled "Bioavailability of EPA + DHA in a SMEDS Formulation". This study will assess the relative bioavailability of 500 mg eicosapentaenoic acid (EPA) + docosahexaenoic acid (DHA) in a self-micro-emulsifying delivery system (SMEDS) formulation compared with a standard omega-3-acid ethyl ester product in healthy men and women.
What is the current status of trial NCT03443076?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2018-02-16. Estimated completion is 2018-04-15.
What conditions does trial NCT03443076 study?
This clinical trial studies the following conditions: Bioavailability.
What interventions are being tested in trial NCT03443076?
The interventions under investigation include: EPA + DHA in SMEDS Formulation (DIETARY_SUPPLEMENT), Lovaza (active comparator; already FDA approved) (OTHER).
Who is sponsoring clinical trial NCT03443076?
This trial is sponsored by Midwest Center for Metabolic and Cardiovascular Research, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03443076 being conducted?
This trial has 2 study locations across Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bioavailability
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Bioavailability of Ration Items Containing Tart Cherry Extract
RECRUITING · NA
-
Curcumin and Retinal Study
RECRUITING · Phase 1
-
A Study of TEPEZZA Subcutaneous Administration in Healthy Adults
COMPLETED · Phase 1
-
A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects
COMPLETED · Phase 1
-
Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
COMPLETED · Phase 1
-
Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.